Table 5 Hazard ratios of overall survival and GISTs-specific survival among patients with AM-GISTs, stratified by sites of the first malignancy, compared with those with GISTs only
Overall survival* | GISTs-specific survival* | |||
|---|---|---|---|---|
Covariates | HR (95% CI) | p | HR (95% CI) | p |
GISTs-1 | Reference | Reference | ||
AM-GISTs | ||||
By sites of the first malignancy | ||||
Prostate | 0.87 (0.70–1.07) | 0.179 | 0.68 (0.51–0.91) | 0.009 |
Breast | 0.90 (0.66–1.21) | 0.469 | 0.79 (0.53–1.17) | 0.237 |
Large intestine | 1.24 (0.90–1.71) | 0.191 | 0.52 (0.27–0.99) | 0.050 |
Urinary system | 1.24 (0.88–1.76) | 0.224 | 0.85 (0.51–1.42) | 0.535 |
Hematological system | 1.66 (1.11–2.49) | 0.014 | 1.25 (0.69–2.27) | 0.455 |
Reproductive system | 1.85 (1.25–2.73) | 0.002 | 0.95 (0.49–1.84) | 0.877 |
Melanoma of the skin | 0.75 (0.49–1.16) | 0.192 | 0.33 (0.15–0.75) | 0.007 |
Others | 1.76 (1.34–2.30) | < 0.001 | 0.67 (0.40–1.14) | 0.143 |